Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients have?
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients has 138 citations in the OpenAlex counts ScholarIQ stores.
When was Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients published?
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients has 2018 year in the ScholarIQ index.
What is the open-access status of Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients?
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients has gold oa status in the ScholarIQ index.
What is the DOI of Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients?
The DOI for Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients is on the source record.
What is the PMID of Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients?
The PMID for Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients is on the source record.
What is the OpenAlex record for Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients?
The OpenAlex for Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients is on the source record.